TVM Capital

Life Sciences

Equity Financing Solutions for the Life Science & Healthcare industries

The TVM Capital Life Science & Healthcare Practice is a dedicated provider of life science venture capital and healthcare private equity to the international pharmaceutical, biopharmaceutical, medical technology and healthcare services industries.

The TVM Capital Life Science & Healthcare Practice currently manages €860 million (US$1.3bn) of committed capital from more than 50 investors. Our investment professionals draw upon the experience, international approach and demonstrated success of more than 70 exits from 110 investments during more than 25 years. This includes 37 initial public offerings on the Nasdaq, and the London, Frankfurt, Zurich and Vienna Stock Exchanges and 24 trade sales. The two teams combine this long-standing international investment experience and operating track records with extensive global networks and knowledge of local markets. For more than 20 years, our mission has been to invest in the development and growth of exciting companies who are or aspire to be leaders in their market segment, and to be resourceful and supportive strategic partners to founders, owners and managers alike.

The operating entity of TVM Capital for private equity investments in healthcare services and pharmaceutical companies in the Middle East and Northern Africa is TVM Capital MENA Ltd., Dubai.

Life Science Venture Capital
Creating value through long-standing investment experience and the application of new capital efficiency models in the financing of product innovation.

The TVM Capital Life Science team successfully pioneered biotech venture investing in Germany and Europe. From its starting point as an investor in entrepreneurial discovery-stage venture capital companies in the early nineties, our investment strategy over the years has morphed into a multi-stage investment approach spanning discovery and development stage companies with diversified product portfolios, technology platforms, single drug development projects as well as investments in market ready products in the pharma and medtech markets.

Today, capital efficiency is paramount for the discovery and development stage biotech industry today —smaller internal teams, strong international networks and international off-shoring and outsourcing are key instruments to reach this objective. At a time when every step of the pharmaceutical industry value chain is a service business, capital efficiency questions in development must be addressed differently. Deriving maximum value through capital efficient and risk balanced investing in project focused R&D stage pharmaceutical assets is our answer to the life science industry investment paradigm shift.

With more than two decades of experience in building entrepreneurial companies, we are astute at identifying opportunities to take projects and companies to value inflection points. This is coupled with the ability to finance a company through the more capital intensive stages of development, from our own investment funds and a strong syndication capability—enabling our portfolio companies to fully realize their potential.

Healthcare Private Equity
Combining deep industry expertise with strong financial skills for growth and profitability driven private equity transactions in the European healthcare market

In Europe, the healthcare industry is dominated by small and medium-sized entrepreneurial and family-owned businesses (SMEs). Many of these companies are highly profitable and have been growing successfully for many decades. These companies still enjoy excellent growth prospects based on their world leading quality, innovation strong manufacturing base and leading market positions. At the same time globalization and cost pressures in many of the sub-segments of the healthcare markets pose increasing challenges to prolonged success. This situation - requiring new strategies, including international partnering, access to new markets and products and new growth financing - represents a natural opportunity for a highly specialized investment team that offers to company owners and management teams new ways of looking at their growth and financing strategies.

TVM Capital is a highly attractive partner for European SMEs in the healthcare industry that are considering private equity transactions at a time when there is already substantial industry to industry deal making and restructuring activities. Our focus is on providing flexible and custom-made solutions to SME challenges, including restructuring of shareholder groups to opening of new avenues for growth. For large corporations in the healthcare industry, we are an excellent partner for strategic transactions resulting from internal refocusing, strategic divestiture of products, product portfolios or entire business units.

Private equity transactions in healthcare require deep industry knowledge and networks. During the last 20 years, and in particular since 2007 when we started to extend our focus from venture capital to financing growth in mid-market companies, we have built excellent and far reaching relationships in the European and U.S. industry, as well as established a network of collaborators and partners in some of the fastest growing emerging healthcare markets of the world: India, East Asia and the MENA region. This is an important component of our ability to actively work with industry partners – small and large – to create new business concepts, strategies and opportunities for growth and profitability.

Our approach is well regarded in the industry, resulting in several noted awards. TVM Capital is Private Equity International’s “German Private Equity Firm of the Year 2008”, was ranked 18th in the list of the leading 100 venture capital companies in the world by Red Herring Magazine in September 2009, and received the M&A Advisor Corporate/Strategic Acquisition of the Year Award in December 2009 for the $300 million acquisition of portfolio company Direvo Biotech AG by Bayer HealthCare AG in September 2008.